Adam Renslo
banner
renslolab.bsky.social
Adam Renslo
@renslolab.bsky.social
chemical biology and medicinal chemistry @UCSF
Pinned
The version of record is now out in eLife! For the next chapter in this story check out www.biorxiv.org/content/10.1...

In @elife.bsky.social: The Mac1 ADP-ribosylhydrolase is a therapeutic target for SARS-CoV-2 doi.org/10.7554/eLif...
The Mac1 ADP-ribosylhydrolase is a therapeutic target for SARS-CoV-2
The development of new small molecules demonstrates how pharmacologic inhibition of the coronavirus macrodomain restores innate immunity, leading to reduced viral replication and improved outcomes in ...
doi.org
The version of record is now out in eLife! For the next chapter in this story check out www.biorxiv.org/content/10.1...

In @elife.bsky.social: The Mac1 ADP-ribosylhydrolase is a therapeutic target for SARS-CoV-2 doi.org/10.7554/eLif...
The Mac1 ADP-ribosylhydrolase is a therapeutic target for SARS-CoV-2
The development of new small molecules demonstrates how pharmacologic inhibition of the coronavirus macrodomain restores innate immunity, leading to reduced viral replication and improved outcomes in ...
doi.org
November 20, 2025 at 9:02 PM
Check out our latest work on endoperoxide antimalarials - Congrats to Matt, Poulami, and many other lab members and collaborators!

Identifying a next-generation antimalarial trioxolane in a landscape of artemisinin partial resistance | Science Advances www.science.org/doi/10.1126/...
Identifying a next-generation antimalarial trioxolane in a landscape of artemisinin partial resistance
Antimalarial endoperoxides with activity against artemisinin-resistant clinical isolates are characterized in vitro and in vivo.
www.science.org
August 8, 2025 at 11:18 PM
Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus MPro inhibitors with potent in vivo efficacy | Science Advances www.science.org/doi/10.1126/...
Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus MPro inhibitors with potent in vivo efficacy
This study describes a class of potent, bioavailable SARS-CoV-2 MPro inhibitors having an unusual mechanism of inhibition.
www.science.org
April 26, 2025 at 1:15 AM